Dr. Shah Discusses Sequencing for MCL

Bijal D. Shah, MD
Published: Friday, Nov 17, 2017



Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).

The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.
 
SELECTED
LANGUAGE


Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the sequencing of agents for patients with mantle cell lymphoma (MCL).

Sequencing will play a role in determining which treatments to give to patients with MCL. According to Shah, clinically, a patient with a p53 mutation should first receive lenalidomide (Revlimid).

The next big biomarker will be the ColonoSEQTM minimal residual disease (MRD) approach to assess death of remission, explains Shah.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x